Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
54 hedge funds and large institutions have $37.9M invested in Merrimack Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 10 closing their positions.
124% more call options, than puts
Call options by funds: $110K | Put options by funds: $49K
59% more capital invested
Capital invested by funds: $23.8M → $37.9M (+$14.1M)
4% less funds holding
Funds holding: 56 → 54 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
+$2M |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$1.61M |
| 3 |
NM
Newtyn Management
New York
|
+$1.5M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$486K |
| 5 |
Invesco
Atlanta,
Georgia
|
+$339K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$2.79M |
| 2 |
SC
Sepio Capital
Salt Lake City,
Utah
|
-$1.59M |
| 3 |
CC
Clearline Capital
New York
|
-$1.22M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$587K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$233K |
MACK Hedge Fund Activity: Q1 2019 in Review
54 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2019, worth a combined $37.9M — up 59% from $23.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of MACK and 8 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 11 added.
The largest buyer was 22NW LP, adding an estimated $2M. The largest seller was BVF Inc, exiting entirely with an estimated $2.79M sold.
- 54 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2019, down from 56 in Q4 2018.
- Funds reported $37.9M of Merrimack Pharmaceuticals, Inc. stock for Q1 2019, up 59% quarter-over-quarter.
- 8 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2019 and 10 closed out, a net change of -2 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2019 was 22NW LP, an estimated $2M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2019 was BVF Inc, an estimated $2.79M sold.
Based on aggregated 13F filings for Q1 2019.